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Background
The SARA trial recently demonstrated a non-inferior
CD4 response, over median follow-up of 60 weeks, with
a boosted protease inhibitor monotherapy (bPImono)
maintenance second-line regimen compared with con-
tinuous combination therapy (CT), suggesting this
approach could maintain effectiveness whilst improving
tolerability and decreasing costs [International AIDS
Conference 2010, LBPE16]. Analysis of virological
response and genotypic drug resistance is reported here.
Methods
Eligible participants in the DART trial who received 24
weeks of lopinavir/ritonavir-containing second-line CT
were randomised to maintain current CT or to reduce
to bPImono within a nested pilot trial (SARA). No real-
time virology was performed, but stored plasma samples
from time at switch to second-line, randomisation after
24 weeks of second-line, and 24 weeks after randomisa-
tion were assayed for HIV-1 RNA viral load (VL) by
Roche Amplicor v1.5. Genotypic resistance was assessed
on samples with VL >1000 c/ml at this latest time
point, along with paired samples at switch to second-
line. All analyses are intention-to-treat.
Results
192 participants were randomised to CT (n=95) or bPI-
mono (n=97). 77% (135/173) had VL<50 c/ml at randomi-
sation. 44 (23%) participants were taking bPI with NRTI
only, 29 (15%) with NNRTI only, and 119 (62%) with both.
Virological suppression at week 24 was higher (trend test
p=0.007) for participants on CT vs bPImono: 77% (70/91)
vs 60% (56/94) had VL <50 c/ml, 90% (82) vs 74% (72) had
VL <200 c/ml, and 94% (86) vs 84% (81) had VL <1000 c/
ml. Restricting to patients with VL <50 c/ml at randomisa-
tion, 85% (57/67) vs 66% (43/65) had VL <50 c/ml at week
24. Of the 18 participants with VL >1000 c/ml at week 24,
12 (2 CT, 10 bPImono) have been assessed genotypically.
IAS major PI mutations at week 24, not present at switch
to second-line, were detected in 2 bPImono participants
only. One participant (VL=3600 c/ml) had I54V only, the
other (VL=1490 c/ml) M46IM+V82AV. Both isolates were
considered fully susceptible to darunavir.
Conclusions
In this study based on retrospective virological testing,
bPImono following 24 week second-line induction was
associated with an increase in low level viraemia, although
generally in the absence of PI resistance. Longer-term
trials are required before definitive conclusions can be
drawn about the effectiveness of PI monotherapy in popu-
lations without access to virological monitoring.
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